Terconazole, an azole antifungal drug, increases cytotoxicity in antimitotic drug-treated resistant cancer cells with substrate-specific p-gp inhibitory activity

HIGHLIGHTS

• who: Ji Sun Lee et al. from the School of Pharmacy, Sungkyunkwan University, Seobu-ro, Jangan-gu, Suwon, Korea have published the research work: Terconazole, an Azole Antifungal Drug, Increases Cytotoxicity in Antimitotic Drug-Treated Resistant Cancer Cells with Substrate-Specific P-gp Inhibitory Activity, in the Journal: (JOURNAL)
• what: The authors examined whether TCZ, an FDA-approved drug, increases the cytotoxicity of antimitotic drugs in P-gp-overexpressing MDR cancer cells.
• how: The authors investigated whether azole antifungal drugs could inhibit P-gp activity in MDR cancer cells using two different P . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.